Evidence map›Paper›PMID 26194361›Full record

Trial reportThe pharmacogenomics journal2016

Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.

Y J He, S J Winham, J M Hoskins, S Glass, J Paul, R Brown, A Motsinger-Reif, H L McLeod

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Novel molecular biomarkers associated with Taxane-induced toxicities in women with breast cancer from the Brazilian Amazon.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Analyses ofHuman mutation · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Y J HeDepartment of Clinical Pharmacology, Xiang-Ya Hospital, Central South University, Changsha, China.
S J WinhamBioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, USA.
J M HoskinsInstitute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA.
S GlassInstitute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA.
J PaulCancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
R BrownDepartment of Surgery and Cancer, Imperial College London, London, UK.
A Motsinger-ReifBioinformatics Research Center, Department of Statistics, North Carolina State University, Raleigh, NC, USA.
H L McLeodDepartment of Clinical Pharmacology, Xiang-Ya Hospital, Central South University, Changsha, China.
North Carolina State University · USUniversity of North Carolina at Chapel Hill · USAdventHealth Tampa · USBeatson West of Scotland Cancer Centre · GBImperial College London · GBPharmacoGenetics (China) · CN

Funding

Biostatistics Training in the Omics EraT32GM081057 · NIGMS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI MUSE, SPENCER V. · 2007 to 2019
$2.5M
Cancer Research UK 13086Cancer Research UK 15960NIGMS NIH HHS T32 GM081057
6 · The paper itself

Abstract

Carboplatin/taxane combination is first-line therapy for ovarian cancer. However, patients can encounter treatment delays, impaired quality of life, even death because of chemotherapy-induced gastrointestinal (GI) toxicity. A candidate gene study was conducted to assess potential association of genetic variants with GI toxicity in 808 patients who received carboplatin/taxane in the Scottish Randomized Trial in Ovarian Cancer 1 (SCOTROC1). Patients were randomized into discovery and validation cohorts consisting of 404 patients each. Clinical covariates and genetic variants associated with grade III/IV GI toxicity in discovery cohort were evaluated in replication cohort. Chemotherapy-induced GI toxicity was significantly associated with seven single-nucleotide polymorphisms in the ATP7B, GSR, VEGFA and SCN10A genes. Patients with risk genotypes were at 1.53 to 18.01 higher odds to develop carboplatin/taxane-induced GI toxicity (P<0.01). Variants in the VEGF gene were marginally associated with survival time. Our data provide potential targets for modulation/inhibition of GI toxicity in ovarian cancer patients.

Indexed as

PharmacogeneticsPolymorphism, Single NucleotideAdenosine TriphosphatasesAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCation Transport ProteinsCopper-Transporting ATPasesDocetaxelFemaleGastrointestinal DiseasesGenetic Association StudiesGenetic Predisposition to DiseaseHumansKaplan-Meier EstimateNAV1.8 Voltage-Gated Sodium ChannelOvarian NeoplasmsAdenosine TriphosphatasesATP7B protein, humanCarboplatinCation Transport ProteinsCopper-Transporting ATPasesDocetaxelNAV1.8 Voltage-Gated Sodium ChannelSCN10A protein, humanTaxoidsVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID26194361
OpenAlexW1595835384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.